NASDAQ:FIXX - Homology Medicines Stock Price, Forecast & News

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines Inc (NASDAQ:FIXX) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.09. The business earned $0.44 million during the quarter, compared to the consensus estimate of $0.38 million. Homology Medicines had a negative return on equity of 43.33% and a negative net margin of 4,740.81%. View Homology Medicines' Earnings History.

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Homology Medicines.

6 equities research analysts have issued twelve-month price objectives for Homology Medicines' shares. Their forecasts range from $29.00 to $37.00. On average, they expect Homology Medicines' share price to reach $33.00 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price. View Analyst Price Targets for Homology Medicines.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Press coverage about FIXX stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Homology Medicines earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Homology Medicines.

Homology Medicines saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,050,000 shares, an increase of 6.6% from the December 15th total of 2,860,000 shares. Based on an average daily trading volume, of 341,000 shares, the days-to-cover ratio is currently 8.9 days. Approximately 10.1% of the shares of the company are sold short. View Homology Medicines' Current Options Chain.

Some companies that are related to Homology Medicines include Alkermes (ALKS), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Epizyme (EPZM), ArQule (ARQL), Zogenix (ZGNX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), Karuna Therapeutics (KRTX), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH) and Heron Therapeutics (HRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Editas Medicine (EDIT), Stag Industrial (STAG), NVIDIA (NVDA), Pfizer (PFE), AT&T (T), Verizon Communications (VZ), Exxon Mobil (XOM) and Nektar Therapeutics (NKTR).

(FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Alpine Global Management LLC (0.03%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am, Vida Ventures, Llc and W Bradford Smith. View Institutional Ownership Trends for Homology Medicines.

FIXX stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FIXX stock can currently be purchased for approximately $15.71.

Homology Medicines has a market capitalization of $691.71 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.

The official website for Homology Medicines is http://www.homologymedicines.com/.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.